Letter to the Editor: EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.
作者信息
Daungsupawong Hinpetch, Wiwanitkit Viroj
机构信息
Private Academic Consultant, Phonhong, Lao People's Democratic Republic.
Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
出版信息
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241292706. doi: 10.1177/15330338241292706.
Abstract
摘要
相似文献
1
Letter to the Editor: EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.致编辑的信：表皮生长因子受体酪氨酸激酶抑制剂联合异体CD8+自然杀伤T细胞免疫疗法治疗晚期表皮生长因子受体突变型肺癌患者
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241292706. doi: 10.1177/15330338241292706.
2
EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂联合同种异体 CD8+NKT 细胞免疫治疗晚期表皮生长因子受体突变型肺癌。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241273198. doi: 10.1177/15330338241273198.
3
A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.一项关于 NKT 细胞联合吉非替尼治疗晚期 EGFR 突变型非小细胞肺癌的疗效和安全性的 I/II 期临床试验。
BMC Cancer. 2021 Jul 31;21(1):877. doi: 10.1186/s12885-021-08590-1.
4
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
5
Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis.局部颅脑放疗联合第三代酪氨酸激酶抑制剂可提高表皮生长因子受体（EGFR）突变的非小细胞肺癌脑转移患者的软脑膜转移无病生存期。
J Neurooncol. 2025 Jun 18. doi: 10.1007/s11060-025-05045-6.
6
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.厄洛替尼或吉非替尼治疗铂类预处理复发的非小细胞肺癌和卵巢癌：系统评价。
Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24.
7
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.厄洛替尼、吉非替尼、阿法替尼和埃克替尼用于携带EGFR突变的晚期非小细胞肺癌患者的网状Meta分析。
PLoS One. 2014 Feb 12;9(2):e85245. doi: 10.1371/journal.pone.0085245. eCollection 2014.
8
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations.携带EGFR突变患者的T细胞免疫与EGFR-TKI耐药获得持续时间之间的相关性。
Cancer Immunol Immunother. 2025 Jul 12;74(8):265. doi: 10.1007/s00262-025-04113-0.
9
[Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].基于TCGA数据库的EGFR突变型与EGFR野生型肺腺癌患者免疫微环境比较研究
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):236-244. doi: 10.3779/j.issn.1009-3419.2021.102.15.
10
Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.异体自然杀伤 T 细胞在治疗吉非替尼敏感肺腺癌患者中的作用。
Immunotherapy. 2022 Nov;14(16):1291-1296. doi: 10.2217/imt-2022-0178. Epub 2022 Sep 28.
本文引用的文献
1
EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂联合同种异体 CD8+NKT 细胞免疫治疗晚期表皮生长因子受体突变型肺癌。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241273198. doi: 10.1177/15330338241273198.
Zotero 插件